Navigation Links
Merz, Inc. Announces Cynthia Schwalm as Vice President, Neurology
Date:9/17/2012

GREENSBORO, N.C., Sept. 17, 2012 /PRNewswire/ -- Merz, Inc. (U.S. affiliate of Merz Pharma Group) today announced the appointment of Cynthia Schwalm has as vice president, neurology effective immediately. Schwalm will be responsible for the Merz's growing neurology business unit in the U.S., which includes the recently acquired product CUVPOSA®.

"Cynthia brings national as well as international experience, in developing and commercializing pharmaceutical products. We are extremely pleased to have her join the Merz team and are confident she will make immediate and important contributions to steer the future growth of our neurology business and the company as a whole," said Bill Humphries, president & CEO of Merz, Inc.

Humphries noted that he will name his entire North American Leadership Team within the next few months as Merz, Inc. and its U.S. affiliates continue to undergo integration in preparation for accelerated growth opportunities across all business units.

Prior to joining Merz, Schwalm was the Senior Advisor to the Chief Executive Officer at Chimerix, Inc. She has held various international commercial leadership and general management positions with Optimer, Eisai, Amgen, and Johnson & Johnson. Schwalm brings with her 30 years of experience in the pharmaceutical and healthcare industry, with commercialization experience in movement disorders and neurology including pain management, Alzheimer's disease, and epilepsy including Lennox Gaustaut syndrome.

Schwalm obtained her Bachelor of Science in Nursing from the University of Delaware in Newark, DE. She also earned her Executive Master of Business Administration from the Wharton School of Business from the University in Pennsylvania in Philadelphia, PA. Schwalm is a member for Beth Abraham Family Health Services Board and Sarah Cannon Oncology Research Institute Board. She will be based out of the office in Greensboro, NC.

About Merz, Inc.

Merz, Inc. is responsible for developing and commercializing products in the U.S. for Merz Pharma Group. Areas of therapeutic focus include Neurology, Physiatry, Dermatology, Aesthetics, and Podiatry.

About Merz Pharma Group

Globally, the companies of Merz Pharma Group are focused on medications for treating neurological and psychiatric illnesses and thereby assume a leading role in the field of Alzheimer research.  Another important area of competency of Merz is Clinical Dermatology and Aesthetic Medicine. Merz is also active in the Health sector outside of the pharmacy. In the field of consumer products, with its established brands of tetesept® and Merz Spezial®, Merz Consumer Care is a leading provider of products for self-medication, nutritional supplements and skin care in the German-speaking area. Merz Pharma Group is a privately owned company, founded in 1908 in Frankfurt, Germany.


'/>"/>
SOURCE Merz, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Merz, Inc. Announces Promotion of Katrina Church to Vice President, Chief Compliance Officer
2. Heska Corporation Announces Amendment To Its Odd-Lot Tender Offer
3. Onconome Announces Results Of Blood Test For Colorectal Cancer; Further Trials Underway
4. Valeant Pharmaceuticals Announces Management Change
5. Neuralstem Announces Proposed Public Offering
6. PPCE Announces Strategic Partnership With ECLINSO AG
7. Agendia Announces Five Studies in Breast Cancer for Presentation at the American Society of Clinical Oncology 2012 Breast Cancer Symposium
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Soligenix Announces Issuance of US Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
10. Henry Schein Announces New $500 Million Credit Facility
11. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... YORK , Jan. 19, 2017 This ... the current and future scenario of the global market. ... rising opioid consumption. Severe chronic constipation is a major ... to traditional laxatives. Hence, novel targeted therapy has been ... OIC sufferers, launch of targeted medicines, and growing awareness ...
(Date:1/19/2017)... 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ), ... dysfunction, today announced new additions to its senior leadership ... Medical Officer, and Daniel Geffken as interim ... Jim Carr , Pharm.D. has been promoted to Chief ... to welcome Doug and Daniel to our management team, ...
(Date:1/19/2017)... January 19, 2017 According to a study ... is set to witness a CAGR of 6.5% during the forecast ... will continue to be the leading market for cryotherapy globally ... ... emphasizing on ensuring affordable and adequate supply of gas in order ...
Breaking Medicine Technology:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... International Protein, ... nutritional and bodybuilding supplements, announced it attended the January ECRM trade show in Hilton ... and nutritional scientist who was determined to create a line of products that would ...
(Date:1/20/2017)... ... , ... “Mary Magdalene: Grace is Greater than Sin”: a unique and ... Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the creation of published ... with countless women who had little knowledge of the female characters portrayed in the ...
(Date:1/20/2017)... Farmville, NC (PRWEB) , ... January 20, 2017 ... ... the vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in ... article by Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive ...
(Date:1/20/2017)... ... 20, 2017 , ... “The Land of More and More”: a brilliant ... hunger, and shares the simple and achievable answer. “The Land of More and More” ... Fairview Missionary Church in Angola, Indiana where he works with the children’s ministry department. ...
(Date:1/19/2017)... ... 19, 2017 , ... Next week after January 20th, the fear for many ... that circumvent health needs of over 30 million. Many interviews with Dr. Carol Francis ... government public servants were suppose to prioritize. Interviews provided below. , Among ...
Breaking Medicine News(10 mins):